Eli Lilly and Company (LLY) Investor Update summary

Strategic Focus and Cardiometabolic Health Strategy

• Emphasis on expanding the cardiometabolic health portfolio, targeting obesity, diabetes, and related conditions with a broad, segmented pipeline of tailored therapies.

• Focus on providing freedom from diabetes, eliminating obesity-related health issues, and reducing cardiovascular deaths.

• Estimated addressable market of over 170 million by 2030 in the US, with global potential exceeding 1 billion.

• Obesity market expected to segment based on patient needs, with current penetration at 5% of the 2030 market.

Pipeline and Development Programs

• Portfolio includes orforglipron, tirzepatide, retatrutide, bimagrumab, and eloralintide, targeting obesity, diabetes, and related conditions.

• Orforglipron, an oral GLP-1 agonist, is being developed for obesity, type 2 diabetes, sleep apnea, and hypertension, with a global launch planned and manufacturing investments to support scale.

• Orforglipron and retatrutide are planned for launch by end of 2027, with multiple Phase 3 data readouts in 2025.

• Pipeline includes next-generation incretins, amylin agonists, activin receptor modulators, and once-weekly insulin, aiming to address diverse patient needs and preferences.

• Exploration of new therapeutic areas for incretins, such as brain health, inflammation, pain, and substance use disorder, based on emerging data.

Clinical Development and Trial Updates

• Orforglipron's phase 3 program involves over 11,000 patients, with submissions for chronic weight management expected later this year and for type 2 diabetes in 2026.

• ACHIEVE-1 trial showed significant HbA1c and body weight reductions versus placebo, with dose-dependent effects and safety/tolerability consistent with GLP-1 class.

• Attain One/ATTAIN-1 study in obesity (without diabetes) is ongoing, with topline results expected in Q3 2025; dosing strategy adjusted for optimal weight reduction.

• Retatrutide, a triple agonist, is advancing with multiple phase 3 studies, including unique basket trials for sleep apnea and osteoarthritis, and enriched for high-BMI patients.

• SURPASS CVOT compares tirzepatide to dulaglutide for cardiovascular outcomes, supporting regulatory submissions for CV benefit, with top-line data expected in Q3.